ERBB2 and non-small cell lung carcinoma: On August 11, 2022, the US FDA officially approved the listing of ENHERTU (code DS8201, fam - trastuzumab deruxtecan - nxki, Chinese name: fam - trastuzumab deruxtecan for injection) for adult patients with inoperable and treated HER2 - positive non - small cell lung cancer (NSCLC).